AMENDMENTS TO THE SPECIFICATION

Please replace paragraphs **[0048]** through **[0052]** as follows:

[0048] The following table is from Renkvist *et al.* (2001).

Table 1 Class I HLA-restricted cancer/testis antigens. All these antigens were found to be expressed by normal spermatocytes and/or spermatogonia of testis. Occasionally *MAGE-3, MAGE-4* and the *GAGE* genes were found to be expressed also in placenta (De Backer *et al.*, 1999; Cox *et al.*, 1994). The NY-ESO-1 antigen was found to be expressed in normal ovary cells (Chen *et al.*, 1997).

Gene	HLA allele	Peptide epitope	Authors	Tissue distribution among tumors[a]
MAGE-A1	A1	EADPTGH-SY	Traversari *et al.* 1992	Melanoma, breast carcinoma, SCLC (De Plaen *et al.*, 1999); De Smet *et al.*, 1994, van der Bruggen *et al.*, 1994a) – sarcoma, NSCLC (De Plaen *et al.*, 1999), De Smet *et al.*, 1994) – thyroid medullary carconoma (van der Bruggen *et al.*, 1994a) – colon carcinoma (De Plaen *et al.*, 1999) – laryngeal tumors (De Smet *et al.*, 1994)
MAGE-A1	A3	SLFRAVI-TK	Chaux *et al.* 1999a	
MAGE-A1	A24	NYKHCFP-EI	Fujie *et al.* 1999	
MAGE-A1	A28	EVYDGR-EHSA (SEQ ID NO:15)	Chaux *et al.* 1999a	
MAGE-A1, -A2, -A3, -A6	B37	REPVTKA EML (SEQ ID NO:16)	Tanzarella *et al.* 1999	Melanoma, colon and breast carcinomas, SCLC (De Plaen *et al.*, 1999, De Smet *et al.*, 1994, van der Bruggen *et al.*, 1994a) – sarcoma, NSCLC (De Plaen *et al.*, 1999, De Smet *et al.*, 1994 – thyroid medullary carcinoma, H/N tumors, bronchial SCC (van der Bruggen *et al.*, 1994a) – laryngeal tumors (De Smet *et al.*, 1994) – leukemias (De Plaen *et al.*, 1994)
MAGE-A1	B53	DPARYEF-LW	Chaux *et al.* 1999a	Melanoma, breast carcinoma, SCLC (De Plaen *et al.*, 1999, De Smet *et al.*, 1994, Van den Eynde *et al.*, 1999) – sarcoma, colon carcinoma, NSCLC (De Plaen *et al.*, 1999, De Smet *et al.*, 1994) – thyroid medullary carcinoma (van
MAGE-A1	Cw2	SAFPTTIN-F	Chaux *et al.* 1999a	
MAGE-A1	Cw3	SAYGEPR-KL	Chaux *et al.* 1999a	
MAGE-A1	Cw16	SAYGEPR-KL	van der Bruggen *et al.*	

			1994b	der Bruggen *et al.*, 1994a)
MAGE-A2	A2	KMVELV-HFL	Visseren *et al.* 1997	Melanoma, colon and breast carcinomas, SCLC (De Plaen *et al.*, 1999, De Smet *et al.*, 1994, van der Bruggen *et al.*, 1994a) – sarcoma, NSCLC (De Plaen *et al.*, 1999, De Smet *et al.*, 1994) – thyroid medullary carcinoma (van der Bruggen *et al.*, 1994a)– laryngeal tumors (Lurquin *et al.*, 1997) – leukemias (De Plaen *et al.*, 1999)
MAGE-A2	A2	YLQVFGI-EV	Visseren *et al.* 1997	
MAGE-A2	A24	EYLQLVF-GI	Tahara *et al.* 1999	
MAGE-A3	A1	EADIPIGH LY(SEQ ID NO:17)	Gaugler *et al.* 1994	Melanoma, colon and breast carcinomas (De Plaen *et al.*, 1999, van der Bruggen *et al.*, 1994a) – H/N tumors (Chen *et al.*, 1997) – bronchial SCC, thyroid medullary and bladder carcinoma, sarcomas, SCLC, NSCLC, (van der Bruggen *et al.*, 1994a) – leukemias (De Smet *et al.*, 1994)
MAGE-A3	A2	FLWGPR-ALV	van der Bruggen *et al.* 1994a	
MAGE-A3	A24	TFPDLES-EF	Oiso *et al.* 1999 [	
MAGE-A3	A24	IMPKAGL-LI	Tanaka *et al.* 1997	
MAGE-A3	B44	MEVDPIG-HLY (SEQ ID NO:18)	Hermann *et al.* 1996 Fleischhauer *et al.* 1996	
MAGE-A3	B52	WQYFFP VIF	Russo *et al.* 2000	
MAGE-A4	A2	GVYDGR EHTV (SEQ ID NO:19)	Duffour *et al.* 1999	Melanoma, NSCLC, sarcomas, esophageal, colon and breast carcinomas (De Plaen *et al.*, 1999)
MAGE-A6	A34	MVKISGG PR	Zorn and Hercent, 1999b	Melanoma, NSCLC, colon carcinoma, leukemias (De Plaen *et al.*, 1999)
MAGE-A10	A2	GLYDGM EHL	Huang *et al.* 1999	Not defined
MAGE-A12	Cw7	VRIGHLY IL	Panelli *et al* 2000 Heidecker *et al.* 2000	Melanoma, myeloma, brain tumors, sarcoma, leukemias, SCLC, NSCLC, H/N tumors, bladder, lung, esophageal, breast, prostate and colorectal carcinoma (De Plaen *et al.*, 1994)
BAGE	Cw16	AARAVFL AL	Boer *et al.* 1995	Melanoma, bladder and mammary carcinomas, H/N SCC, NSCLC,

				sarcoma
DAM-6, -10	A2	FLWGPRAYA	Fleischhauer *et al* 1998	Melanoma, skin tumors, mammary and ovarian carcinomas (Lurquin *et al.*, 1997) – lung carcinoma (Dabovic *et al.*, 1995; Lurquin *et al.*, 1997) – seminomas (Dabovic *et al.*, 1995)
GAGE-1, -2, -8	Cw6	YRPRPRRY	Van den Eynde *et al.* 1995 De Backer *et al.* 1999	Melanoma, sarcoma, NSCLC, SCLC, mesothelioma, sarcoma, seminoma, leukemias, lymphomas, H/N tumors, bladder, esophageal, mammary, colon, prostate carcinomas
GAGE-1, -4, -5, -6, -7B	A29	YYWPRPRRY	De Backer *et al* 1999	Melanomas, H/N tumors, leukemias, esophageal, lung and bladder carcinomas
NA88-A	B13	MTQGQHFLQKV (SEQ ID NO:20)	Moreau-Aubrey, *et al.* 2000	Melanoma
NY-ESO-1	A2	SLLMWITQCFL (SEQ ID NO:21)	Jäger *et al.* 1998	Melanoma, sarcoma, B-lymphomas, hepatoma, H/N tumors, bladder, lung, prostate, ovarian, thyroid and breast carcinoma (Chen *et al.*, 1997)
NY-ESO-1a	A2	SLLMWITQC	Jäger *et al.* 1998	
(CAG-3)	A2	QLSLLMWIT	Jäger *et al.* 1998	
	A31	ASGPGGGAPR (SEQ ID NO:22)	Wang *et al.* 1998b	

[a]Tissue distribution among tumors as described in the given references when different from the paper first reporting the sequence of the epitope.

[0049] The following table is from Renkvist *et al.* (2001).

Table 2 Class I HLA-restricted melanocyte differentiation antigens. These antigens can only be expressed in normal and neoplastic cells of the same lineage (namely melanocytes, skin, retina, peripheral ganglia) or in normal cells of the prostate gland.

Gene	HLA allele	Peptide epitope	Authors
MART-1/Melan-A[a]	A2	AAGIGILTV	Coulie *et al.* 1994 Kawakami *et al.* 1994a
	A2	EAAGIGILTV (SEQ ID NO:23)	Schneider *et al.* 1998
	A2	ILTVILGVL	Castelli *et al.* 1995

	B45	AEEAAGIGIL (SEQ ID NO:24)	Schneider *et al.* 1998
	B45	AEEAAGIGILT (SEQ ID NO:25)	Schneider *et al.* 1998
MCIR	A2	TILLGIFFL	Salazar-Onfray *et al.* 1997
	A2	FLALIICNA	Salazar-Onfray *et al.* 1997
Gp100	A2	KTWGQYWQV	Bakker *et al.* 1995
	A2	AMLGTHTMEV (SEQ ID NO:26)	Tsai *et al.* 1997
	A2	MLGTHTMEV	Tsai *et al.* 1997
	A2	SLADTNSLAV (SEQ ID NO:27)	Tsai *et al.* 1997
	A2	ITDQVPFSV	Kawakami *et al.* 1995
	A2	LLDGTATLRL (SEQ ID NO:28)	Kawakami *et al.* 1994b
	A2	YLEPGPVTA	Cox *et al.* 1994
	A2	VLYRYGSFSV (SEQ ID NO:29)	Kawakami *et al.* 1995
	A2	RLMKQDFSV	Kawakami *et al.* 1998
	A2	FLPRIFCSC	Kawakami *et al.* 1998
	A3	LIYRRRLMK	Kawakami *et al.* 1998
	A3	ALNFPGSQK	Kawashima *et al.* 1998
	A3	SLIYRRRLMK (SEQ ID NO:30)	Kawashima *et al.* 1998
	A3	ALLAVGATK	Skipper *et al.* 1996
	A24	VYFFLPDHL	Robbins *et al.* 1997
	Cw8	SNDGPTLI	Castelli *et al.* 1999
PSA	A1	VSHSFPHPLY (SEQ ID NO:31)	Corman *et al.* 1998
	A2	FLTPKKLQCV (SEQ ID NO:32)	Correale *et al.* 1997
	A2	VISNDVCAQV (SEQ ID NO:33)	Correale *et al.* 1997
PSM	A1	HSTNGVTRIY (SEQ ID NO:34)	Corman *et al.* 1998
Tyrosinase	A1	KCDICTDEY	Kittlesen *et al.* 1998
	A1	SSDYVIPIGTY (SEQ ID NO:35)	Kawakami *et al.* 1998
	A2	YMDGTMSQV	Wölfel *et al.* 1994
	A2	MLLAVLYCL	Wölfel *et al.* 1994
	A24	AFLPWHRLF	Kang *et al.* 1995
	B44	SETWRDIDF	Brichard *et al.* 1996
TRP-1 (or gp75)	A31	MSLQRQFLR	Wang *et al.* 1996b
TRP-2	A2	SVYDFFVWL	Parkhurst *et al.* 1998
	A2	TLDSQVMSL	Noppen *et al.* 2000
	A31	LLGPGRPYR	Wang *et al.* 1996a
	A33	LLGPGRPYR	Wang *et al.* 1998a
	Cw8	ANDPIFVVL	Castelli *et al.* 1999

[a]Two different groups simultaneously discovered this gene and gave it two different names, MART-1 and Melan-A respectively

[0050] The following table is from Renkvist *et al.* (2001).

Table 3 Class I HLA-restricted widely expressed antigens

Gene	HLA	Peptide epitope	Tissue distribution		Reference
			Tumors	Normal tissues	
ART-4	A24	AFLRHAAL DYPSLSATDI (SEQ ID NO:36)	SCC, SCLC, H/N tumors, leukemia, lung, esophageal, gastric, cervical, endometrial, ovarian and breast carcinomas	Testis, placenta, fetal liver	Kawano *et al.* 2000
CAMEL	A2	MLMAQEALAF L (SEQ ID NO:37)	Melanoma	Testis, placenta, heart, skeletal muscle, pancreas	Aarnoudse *et al.* 1999
CEA	A2	YLSGANLNL (CAP-1)[a]	Melanoma	Testis, placenta, heart, skeletal muscle, pancreas	Tsang *et al.* 1995
CEA	A3	HLFGYSWYK	Colon, rectum, pancreas, gastric, breast and lung carcinomas	Gastrointestinal embryonic tissue	Kawashima *et al.* 1999
Cyp-B	A24	KFHRVIKDF DFMIQGGDF	Lung adenocarcin oma, T cell leukemia, lymphosarcoma – bladder, ovarian, uterine and esophagela SCC,	Ubiquitously expressed in normal tissues	Gomi *et al.* 1999
HER2/neu	A2	KIFGSLAFL	Melanoma – ovarian and breast carcinomas	Epithelial cells	Risk *et al.* 1995
HER2/neu	A2	IISAVVGIL	Melanoma, ovaria n, pancreatic (Pieper *et al.*, 1999)[b] and breast carcinomas	Epithelial cells	Peoples *et al.* 1995
HER2/neu	A2	RLLQETELV	Melanoma, ovarian, gastric, pancreatic (Pieper	Epithelial cells	Kono *et al.* 1998

			et al., 1999) and breast carcinomas		
HER2/neu	A2	VVLGVVFGI ILHNGAYSL YMIMVKCWMI (SEQ ID NO:38)	Melanoma, ovarian, gastric, pancreatic (Pieper *et al.*, 1999) and breast carcimonas	Epithelial cells	Rongcun *et al.* 1999
HER2/neu	A3	VLRENTSPK	Melanoma, ovarian, gastric, pancreatic (Pieper *et al.*, 1999) and breast carcinomas	Epithelial cells	Kawashima *et al.* 1999
HTERT[c]	A2	ILAKFLHWL	Lung, and ovarian carcinomas – multiple myeloma, melanoma, sarcoma, acute leukemias, non-Hodgkin's lymphomas	Hematopoietic stem cells and progenitors; germinal center cells; basal keratinocytes; gonadal cells; certain proliferating epithelial cells	Vonderheide *et al.* 1999
HTRT[c]	A2	ILAKFLHWL RLVDDFLLV	Lung, prostate and ovarian carcinomas, multiple myeloma, melanoma, sarcoma, acute leukemias, non-Hodgkin's lymphomas	Circulating B cells; germinal center B cells; thymocytes; CD34+ progenitor hemopoietic cells	Minev *et al.* 2000
iCE	B7	SPRWWPTCL	RCC	Kidney, colon, small intestine, liver, heart, pituitary gland, adrenal gland, prostate, stomach	Ronsin *et al.* 1999
MUCI	A11	STAPPAHGV	Breast and ovarian carcinomas, multiple myeloma, B-cell carcinoma, multiple myeloma	None[d]	Domenech *et al.* 1995
MUCI	A2	STAPPVHNV	Breast and ovarian carcinoma, multiple myeloma, B-cell lymphoma	None[d]	Brossart *et al.* 1999
MUC2	A2	LLNQLQVNL MLWGWREHV	Ovary, pancreas and breast	Colon, small intestine,	Böhm *et al.* 1998

			mucinous tumors, colon carcinoma of non-mucinous type	bronchus, cervix and gall bladder	
PRAME	A24	LYVDSLFFL	Melanoma, H/N and lung SCC, NSCLC (van Baren *et al.*, 1998), RCC, adenocarcinoma, sarcoma, leukemias	Testis, endometrium, ovary, adrenals, kidney, brain, skin	Ikeda *et al.* 1997
P15	A24	AYGLDFYIL	Melanoma	Testis, spleen, thymus, liver, kidney, adrenal tissue, lung tissue, retinal tissue	Robbins *et al* 1995
RU1	B51	VPYGSFKHV	Melanoma, renal and bladder carcinomas	Testis, kidney, heart, skin, brain, ovary, liver, lung, lymphocytes, thymus, fibroblasts	Morel *et al.* 2000
RU2	B7	LPRWPPPQL	Melanoma, sarcomas leukemia – brain, esophageal and H/N tumors – renal, colon, thyroid, mammary, bladder, prostatic and lung carcinomas	Testis, kidney, liver, urinary bladder	Van den Eynde *et al.* 1999
SART-1	A24	EYRGFTQDF	Esophageal, H/N and lung SCC – adenocarcinoma, uterine cancer	Testis, fetal liver	Kikuchi *et al.* 1999
SART-1	A*2601	KGSGKMKTE	Esophageal, H/N and lung SCC, adenocarcinoma, uterine cancer	Testis, fetal liver	Shichijo *et al.* 1998
SART-3	A24	VYDYNCHVDL (SEQ ID NO:39) AYIDFEMKI	H/N, esophageal and lung SCC, adenocarcinoma,	Lymphoid cells, fibroblasts, testis, fetal liver	Yang *et al* 1999

			leukemia, melanoma		
WT1	A2	RMFPNAPYL	Gastric, colon, lung, breast, ovary, uterine, thyroid and hepatocellular carcinomas – leukemia (including AML, ALL and CML)	Kidney, ovary, testis, spleen	Oka *et al.* 2000

[a]CAP-1 is an alternative name of this peptide
[b]Tissue distribution among tumors as described in the given references when different from the paper first reporting the sequence of the epitope
[c]Telomerase is expressed in most human tumors: those listed were shown to be susceptible to lysis by cytotoxic T lymphocytes
[d]All epithelial tissues express mucin-like hyperglycosylated molecules

[0051] The following table is from Renkvist *et al.* (2001).

TABLE 4. CLASS I HLA-RESTRUCTED TUMOR-SPECIFIC ANTIGENS, INCLUDING BOTH UNIQUE (CDK-4, MUM-2, β-CATENIN, HLA-A2-R170I, ELF2 M, MYOSIN-M, CASPASE-8, KIAA0205, HSP70-2M) AND SHARED (CAMEL, TRP-2/INT2, GNT-V 250, ANTIGENS

Gene	HLA allele	Peptide epitope	Tissue distribution		Reference
			Tumors	Normal tissues	
AFP	A2	GVALQTMKQ	Hepatocellular carcinoma	Fetal liver	Butterfield *et al.* 1999
ß-Catenin/m	A24	SYLDSGIHF	Melanoma	None	Robbins *et al.* 1996
Caspase-8/m	A2	FPSDSWCYF	H/N tumors	None	Mandruzzato *et al.* 1997
CDK-4/m	A2	ACDPHSGHFV (SEQ ID NO:40)	Melanoma	None	Wõfel *et al.* 1995
ELF2 M	*A68*	ETVSEQSNV	Lung SCC	None	Hogan *et al.* 1998
GnT-V	A2	VLPDVFIRC(V)[a] (SEQ ID NO:41)	Melanoma, brain tumors, sarcoma	Breast and brain (low expression)	Guilloux *et al.* 1996
G250	A2	HLSTAFARV	RCC, colon, ovarian and cervical carcinomas	None	Vissers *et al.* 1991
HSP70-2M	A2	SLFEGIDIY	RCC, melanoma, neuroblastoma	None	Gaudin *et al.* 1999
*HA-A*0201-R1701*	A2	CVEWLRIYLE-NGK (SEQ ID NO:42)	RCC	None	Brãndle *et al.* 1996
HST-2	A31	YSWMDISCWI	Gastric signet cell	None	Suzuki *et al.* 1999

		(SEQ ID NO:43)	carcinoma		
KIAA0205	B44*03	AEPINIQTV	Bladder cancer	None	Gueguen *et al.* 1998
MUM-1	B44	EEKLIVVLF	Melanoma	None	Coulie *et al.* 1995
MUM-2	B44	SELFRSGLDY (SEQ ID NO:44)	Melanoma	None	Coulie *et al.* 1995
MUM-2	Cw6	FRSGLDSYV	Melanoma	None	Chiari *et al.* 1999
MUM-3	A28	EAFIQPITR	Melanoma	None	Baurain *et al.* 2000
Myasin/m	A3	KINKNPKYK	Melanoma	None	Zorn and Hercend, 1999a
RAGE	B7	SPSSNRIRNT (SEQ ID NO:45)	Melanoma, sarcomas, mesotheliomas, H/N tumors, bladder, renal, colon and mammary carcinomas	Retina only	Gaugler *et al.* 1996
SART-2	A24	DYSARWNEI	H/N and lung SCC, lung adenocarcinoma, RCC, melanoma, brain tumors, esophageal and uterine cancers	None	Nakao *et al.* 2000
TRP-2/INT2	A68	AYDFLYNYL SYTRLFLIL EVISCKLIKR (SEQ ID NO:46)	Melanoma	None	Lupetti *et al.* 1998
707-AP	A2	RVAALARDA	Melanoma	None[b]	Morioka *et al.* 1995

[a] VLPDVFIRC(V) = nonamer and decamer peptides are both recognized by CTLs
[b] This antigen is not expressed in normal cells but, as the tissue of the testis was not tested, it will not become clear to which category the antigen may belong until more information is available

[0052] The following table is from Renkvist *et al.* (2001).

TABLE 5. CLASS II HLA-RESTRICTED ANTIGENS

Gene	HLA allele	Peptide epitope	Tissue distribution		Reference
			Tumors	Normal tissues	
Epitopes from normal protein antigens					
Amexin II	DRB*0401	DVPKWISIM-TERSVPH (SEQ ID NO:47)	Melanoma	Not done	Li *et al.* 1998
Gp100	DRB1*0401	WNRQLYPE-WTEAQRLD (SEQ ID NO:48)	Melanoma	Melanocytes	Li *et al.* 1998
MAGE-1, -2, -3, -6	DRB*1301 DRB*1302	LLKYRARIP-VTKAE (SEQ ID NO:49)	Melanoma, lung and breast carcinomas, H/N SCC	Testis, placenta	Chaux *et al.* 1999a
MAGE-3	DR*11-1	TSYVKVLHHM-VKISG	Melanoma, lung and	Testis,	Manici *et*

		(SEQ ID NO:50)	breast carcinomas, H/N SCC	placenta	*al.* 1999
MAGE-3	DRB*1301 DRB*1302	AELVHFLLLK-YRAR (SEQ ID NO:51)	Melanoma, lung and breast carcinomas, H/N SCC	Testis, placenta	Chaux *et al.* 1999b
MART-1 /Melan-A	DRB1*0401	RNGYRALMDKS-LHVGTQCALTRR (SEQ ID NO:52)	Melanoma	Melanocytes	Zarour *et al.* 2000
MUCI	DR3	PGSTAPPAHGVT (SEQ ID NO:53)	Breast and ovarian cancers; multiple myeloma, B-cell lymphoma	None[a]	Hitbold *et al.* 1998
NY-ESO-1	DRB4*0101	VLLKEFTVSG (SEQ ID NO:54)	Melanoma, B-lymphoma, hepatoma (Chen et al., 1997)[b], sarcoma, H/N tumors, - bladder, lunch, prostate, ovarian, thyroid and breast carcinomas	Testis	Zeng *et al.* 2000
NY-ESO-1	DRB4*0101 -0103	PLPVPGVLLK-EFTVSNGI (SEQ ID NO:55) VLLKEFTVSG-NILTIRLT (SEQ ID NO:56) AADHRQLQL-SISSCLQQL (SEQ ID NO:57)	B-Lymphoma, melanoma, sarcoma, H/N tumors, hepatoma (Chen et al., 1997) - bladder, lung, prostate, ovarian, thyroid and breast carcinomas	Testis	Jäger *et al*, 2000
PSA	DR4	ILLGRMSLFM-PEDTG (SEQ ID NO:58) SLFHPEDTGQVFQ (SEQ ID NO:59) QVFQVSHSFPHPLYD (SEQ ID NO:60) NDLMLLRLSEPAELT (SEQ ID NO:61) KKLQCVQLHVISM (SEQ ID NO:62) GVLQGITSMGSEPCA (SEQ ID NO:63)	Melanoma	Melanocytes	Corman *et al.* 1998
Tyrosinase	DRB1*0401	QNILLSNAPLGPQFP (SEQ ID NO:64) DYSYLQDSDPD-SFQD (SEQ ID NO:65) SYLQDSDPDSFQD (SEQ ID NO:66)	Melanoma	Melanocytes	Topalian *et al.* 1994 Topalian *et al.* 1996
Tyrosinase	DRB1*1501	RHRPLQEVYP-EANAPIGHNRE (SEQ ID NO:67)	Melanoma	Melanocytes	Kobayashi *et al.* 1998a
Tyrosinase	DRB1*0405	EIWRDIDFAHE (SEQ ID NO:68)	Melahoma	Melanocytes	Kobayashi *et al.* 1998b

Epitopes from mutated protein antigens

HPV-E7	DR*0401 DR*0407	LFMDTLSFVCPLC (SEQ ID NO:69) LFMDSLNFVCPWC (SEQ ID NO:70)	Cervical carcinomas	None	Höhn *et al.* 1999
CDC27/m	DRB1*0401	FSWAMDLDPKGA (SEQ ID NO:71)	Melanoma	None	Wang *et al.* 1999a
TPI/m	DRB1*0101	GELIGILNAAKVPAD (SEQ ID NO:72)	Melanoma	None	Pieper *et al.* 1999

[a] All epithelial tissues express highly glycosilated mucins whereas tumor cells often show hypoglycosilated mucins with a normal protein sequence.

[b] Tissue distribution among tumors as described in the given references when different from the paper first reporting the sequence of the epitope.